Monoclonal antibody (mAb) products are paramount in the realm of therapeutic treatments, offering hope in the battle against various diseases. However, amidst the advancements in their production processes, the issue of product aggregation looms large, impacting both product efficacy and safety. Aggregates, which are large clusters of denatured antibody molecules, can form during various stages of the bioproduction process, including cell culture, downstream processing, and storage. These aggregates not only lead to product loss but also pose risks to product immunogenicity (1, 2).
The formation of mAb aggregates is a complex interplay of the mAb’s properties and the environmental conditions it encounters during processing and storage. Factors such as pH, ionic strength, temperature, and processing conditions can significantly influence aggregation levels. The challenge lies in monitoring and controlling aggregation throughout the entire manufacturing process to ensure product quality (3).
Aggregation poses a significant concern due to the formation of subvisible particles, which can increase immunogenicity and evade detection by conventional analytical methods. Regulatory agencies emphasize the need to maintain low aggregate levels during mAb manufacturing, typically ranging from 0.5% to 2%. It is essential to differentiate between reversible dimers and trimers, which are less problematic, and irreversible aggregates that can compromise product quality (4, 5).
The bioproduction journey of protein therapeutics exposes them to various stresses, starting from the cell-culture phase where proteins are expressed and secreted into the medium. Subsequent purification steps, such as Protein A chromatography, cation-exchange chromatography, and anion-exchange chromatography, subject the protein to different environmental conditions that can contribute to aggregation. Factors like shear forces, pH shifts, and material interactions play a crucial role in aggregate formation (6).
In the pursuit of understanding and controlling mAb aggregation, it is imperative to delve into the specific factors that contribute to aggregate formation at different stages of the bioproduction process. During product expression, high protein accumulation and cell-culture conditions can induce intracellular aggregation, affecting protein folding and stability. Factors such as temperature, cell-culture medium components, and operating conditions further influence aggregation propensity (7).
Purification steps, including centrifugation and microfiltration, expose the protein to changing environments that can trigger aggregation. pH variations during Protein A chromatography and viral inactivation can destabilize the protein structure, leading to aggregation. Similarly, shear rates during crossflow filtration and adsorption to solid surfaces can promote aggregation through protein denaturation (8, 9).
The complexities of buffer composition and ionic strength are essential considerations in protein stability and aggregation control. pH extremes can induce aggregation, with high ionic strength accelerating the process. Buffer salts, pH adjustments, and specific ions all impact protein stability and aggregation kinetics, necessitating precise control during formulation and manufacturing (10, 11).
The freezing and thawing cycles that proteins undergo during storage and transportation can also induce aggregation. Stress factors such as low temperatures and pH fluctuations can destabilize the protein structure, leading to aggregation upon thawing. Additionally, interactions with container surfaces and ice-liquid interfaces can further contribute to aggregation issues (12, 13).
To mitigate the risks associated with aggregate formation, various strategies for aggregate removal have been implemented in mAb manufacturing. Chromatographic methods, such as cation-exchange chromatography and anion-exchange chromatography, exploit charge differences between mAbs and aggregates to achieve separation. Hydrophobic interaction chromatography (HIC) and mixed-mode chromatography have also emerged as effective tools for reducing aggregate levels (14, 15).
Advanced techniques like aqueous two-phase systems (ATPS) and membrane chromatography offer innovative approaches to aggregate removal. ATPS, despite its complexity, has shown promise in reducing impurities in mAb products. Membrane adsorbers, particularly HIC-based ones, provide high throughput and efficiency in removing dimers and higher molecular weight aggregates during purification (16, 17).
In conclusion, the intricate dance of monoclonal antibody aggregation and removal underscores the importance of meticulous process design and control in biopharmaceutical production. By understanding the underlying factors contributing to aggregation and implementing targeted strategies for aggregate removal, the biopharmaceutical industry can ensure the consistent quality and safety of mAb products.
Key Takeaways:
- Monoclonal antibody aggregation poses challenges in product quality and immunogenicity.
- Factors such as pH, temperature, and processing conditions influence aggregate formation.
- Control measures during various production stages are crucial for mitigating aggregation risks.
- Chromatographic methods and innovative techniques offer solutions for aggregate removal.
- Precise buffer composition and environmental conditions play a critical role in protein stability and aggregation control.
Tags: downstream, bioreactor, biopharma, chromatography, regulatory, cell culture, analytical methods, filtration, bioprocess, biotech
Read more on biopharminternational.com